Grant: Doctoral Research Award: Canada Graduate Scholarships
McMaster University
$105,000.00
miR-299a-5p: a novel mediator of fibrosis in diabetic kidney disease
EF 2022-23
Résumé
As of 2020, Diabetes Canada estimated 11.2 million Canadians live with some form of diabetes, with a rise to 13.5 million by 2030. It was also estimated that the health care cost of treating diabetes and its complications was ~C$3.8b, with a projected rise to C$4.9b by 2030. Diabetes remains the primary cause of kidney failure in adults in North America, with a current need for novel therapeutic targets. Diabetes progresses in the kidneys as diabetic kidney disease. This condition is characterized by increased kidney scaring which eventually leads to kidney decline and failure.
Recently, we have identified an increase in microRNA299a-5p in our chronic kidney disease mouse model and, I have shown a similar increase of this same microRNA in mouse and human diabetic kidneys. MicroRNA's in general are a type of RNA found in cells and blood. They are smaller than many other types of RNA and are known to play specific roles in disease progression. Unfortunately, the role of microRNA299a-5p in diabetic kidney disease is unknown. Therefore, I am hypothesizing that microRNA-299a-5p is an important promoter of kidney failure in diabetes. Inhibition of this microRNA can be beneficial to patients suffering from the disease.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
475456
Name
Nmecha Ifeanyi K
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
miR-299a-5p: a novel mediator of fibrosis in diabetic kidney disease
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Cell Signaling; Chronic Kidney Disease; Diabetes; Diabetic Kidney Disease; Fibrosis; Kidney Disease; Micro-Rna
Abstract
As of 2020, Diabetes Canada estimated 11.2 million Canadians live with some form of diabetes, with a rise to 13.5 million by 2030. It was also estimated that the health care cost of treating diabetes and its complications was ~C$3.8b, with a projected rise to C$4.9b by 2030. Diabetes remains the primary cause of kidney failure in adults in North America, with a current need for novel therapeutic targets. Diabetes progresses in the kidneys as diabetic kidney disease. This condition is characterized by increased kidney scaring which eventually leads to kidney decline and failure.
Recently, we have identified an increase in microRNA299a-5p in our chronic kidney disease mouse model and, I have shown a similar increase of this same microRNA in mouse and human diabetic kidneys. MicroRNA's in general are a type of RNA found in cells and blood. They are smaller than many other types of RNA and are known to play specific roles in disease progression. Unfortunately, the role of microRNA299a-5p in diabetic kidney disease is unknown. Therefore, I am hypothesizing that microRNA-299a-5p is an important promoter of kidney failure in diabetes. Inhibition of this microRNA can be beneficial to patients suffering from the disease.
Competitiondate
202211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Nmecha, Ifeanyi K
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~